| INTRODUCTION
The objectives of this section are to review some of the evidencebased recommendations for sex hormone replacement therapy (i.e., replacement of estrogen and progestin deficiencies) in girls and women with Turner syndrome (TS). We will review some of the benefits of sex hormone replacement therapy, as well as the major risks of sex hormone replacement therapy for individuals with TS.
| BACKGROUND ON ESTROGENS AND PROGESTINS
Estradiol is the natural form of estrogen secreted in the human body, and binds to the estrogen receptors (Rosenfield et al., 1998) . Ethinyl estradiol is a very potent synthetic estradiol analog, but is not metabolized to estradiol itself. Ethinyl estradiol is retained in an unmodified form by the target tissues for much longer than estradiol itself, making it much more potent. On the other hand, the equine estrogens, which are still commonly prescribed, are the major component of the conjugated equine estrogens. These particular estrogens are not estradiol precursors. There are more than 100 types of these equine estrogens, and all have different estrogen receptor affinity and potency. They are also not readily measured in the standard assays that measure estradiol.
The other sex steroid hormone to be considered for replacement therapy in TS individuals is the progestogens or progestins. Progestins can bind to different receptors (Stanczyk, Hapgood, Winer, & Mishell, 2013) . Of course, they bind to the progesterone receptor itself, but in addition there is overlap with binding to the androgen-, glucocorticoid-, and mineralocorticoid receptors. Each progestin-of which there are four different major types or classes, will have differential effects on these various receptors. Progestins together with estrogens make up the oral contraceptive agents (OCPs), and all OCPs will increase the risk of venothrombotic episodes. Combinations of ethinyl estradiol plus third-or fourth-generation progestins have a slightly higher risk for venothrombotic episodes than those OCPs containing first-and second-generation progestins. It is specifically the class of norpregnane derivatives of progesterone that are found to increase the risk for stroke (Practice Committee of the American Society for Reproductive Medicine. Electronic address & Practice Committee of the American Society for Reproductive, 2017). But such information comparing the various progesterone options in OCPs comes from studies with the general female and postmenopausal populations and have not been done in TS patients. Finally, there is crystalline micronized progesterone, which is most often prescribed during the pubertal induction process in girls with ovarian insufficiency, and seems to be associated with a lesser risk for venothrombotic episodes.
| ESTROGEN AND PROGESTIN REPLACEMENT THERAPY IN TURNER SYNDROME
Most TS individuals will need sex steroid hormonal replacement therapy. First and foremost this is necessary for the induction of puberty, but later on for maintaining the secondary sexual characteristics. Sex steroid hormonal replacement therapy is also needed to improve bone mineralization and to allow these young TS women attain a normal peak bone mass by their mid-20s. Estrogen supplementation is further needed to normalize uterine growth and to avoid the other consequences of estrogen deficiency related to the development of the secondary sexual characteristics. In addition, there are positive effects of estrogen supplementation on height outcome and there are important effects on cognitive and memory function (Misra et al., 2011; TorresSantiago et al., 2013) . Despite the importance of adequate estrogen exposure for the benefit of several areas of female health, there are very few randomized controlled trials looking at hormone replacement therapy with estrogen for puberty induction. Not only are there few well-designed studies, those studies that were completed often use different types of estrogen, which makes it difficult to compare the benefits and to assess the risks. Furthermore, all these trials have dealt only with small patient numbers.
3.1 | What is the most desirable way to replace the estrogen deficiency?
Recent data suggest that systemically administered estrogen is a more physiological approach to puberty induction. Estradiol is normally secreted directly into the systemic circulation. If we administer estrogen by using oral preparations to replace the estrogen deficiency, the products will only reach the systemic circulation after absorption into the gastrointestinal tract and passage through the portal venous system. Those estrogens are then metabolized in the liver. This exposes the body, and specifically the liver, to a much greater dose of estrogen compared to systemic administration . Orally administered estrogens, especially ethinyl estradiol, the most commonly used orally administered estrogen, require metabolism in the liver to several metabolites. The oral estrogens have been associated in the general female population with a pro-coagulation state, an increased risk for the development of hypertension, and also an increased risk for venous thromboembolism (Mohammed et al., 2015) .
| TIMING AND DOSING GUIDELINES FOR ESTROGEN/PROGESTIN REPLACEMENT THERAPY IN TS INDIVIDUALS
When starting with therapeutic intervention for pubertal induction in TS, the aim is for initiation of hormone replacement therapy with estrogen between 11 and 12 years of age to mimic average physiology (Cakir, Saglam, Eren, Ozgur, & Tarim, 2015; Gravholt et al., 2017) . This is, of course, recommended only if the girl with TS demonstrates evidence of ovarian dysfunction, as assessed by the finding of an elevated gonadotropin concentration, such as an elevated follicle stimulating hormone (FSH), and a low concentration of anti-Mullerian hormone (AMH). If, on the other hand, the girl has normal gonadotropins for age, it is appropriate to observe for further spontaneous puberty to occur.
Puberty induction should be with low doses of estradiol. That is crucial to preserve growth potential. Transdermal estradiol is the preferred route, preferred over oral estradiol or oral ethinyl estradiol and also, for practical reasons by the patients, over depot-estradiol injections, although the latter can be quite effective for inducing puberty (Rosenfield et al., 1998) . Table 1 Once estrogen replacement therapy has begun, we try to mimic the average progression of puberty. This usually translates into an incremental estrogen dose increase about every 6 months. This continues for about 2-3 years until the girl reaches adult replacement levels. This means that we will be making approximately a 25-100% dose increase every 6 months, about 4-6 times sequentially (Bondy & Turner Syndrome Study, 2007; Gravholt et al., 2017) . It is sufficient to evaluate the individual who is getting estrogen simply from a clinical perspective, and it is not necessary to either measure gonadotropins or estradiol concentrations during puberty induction.
Oral contraceptive pills are not recommended to induce puberty as the dosage of estrogens in OCPs is too high and may therefore have a deleterious effect on growth outcome Trolle, Hjerrild, Cleemann, Mortensen, & Gravholt, 2012) . However, OCPs can be considered for girls who have spontaneous puberty and subsequently develop secondary amenorrhea. They can also be used in TS adults after reaching the adult estrogen dose range and height is not an issue. (Devineni et al., 2007) . It is based on this information that we also recommend to use crystalline progesterone for the initial cycling in adolescent TS individuals.
| BIOLOGICAL CONSEQUENCES OF ESTROGEN THERAPY IN TS INDIVIDUALS
The main objective of sex hormone replacement therapy in TS is to normalize induction of puberty and then normalize the cadence of progression through the puberty years. Several studies have docu- were able to demonstrate that after about 4 years of treatment, a normal uterine volume could be obtained, that is, around 16 years of age (Piippo, Lenko, Kainulainen, & Sipila, 2004) . A handful of studies have also shown that uterine length and uterine volume is not only affected by the type of estrogen, but is also related to the dose used and to the duration of estrogen therapy, so that the adult uterine volume is usually reached after about 4-5 years of estrogen replacement therapy toward a mean estradiol equivalent dose of about 2 mg per day.
Another important effect of estrogen replacement therapy relates to bone health. We know from epidemiological studies that there is an increased prevalence of early fractures in TS individuals, so optimizing estrogen replacement is very important for improving bone mineralization. In one study, girls treated with transdermal estrogen showed a greater increase in their bone mineral density of the lumbar spine compared to girls with oral conjugated estrogens (Nabhan et al., 2009 ). On the other hand, another study in which transdermal estrogen was compared with oral estrogen administration showed no difference over 12 months in change in bone mineral density (TorresSantiago et al., 2013) . We further know that bone mineral density can be maintained in adult TS women if they have appropriate continuation of estrogen replacement therapy, and have a healthy lifestyle with appropriate intake of calcium and vitamin D. This effect is observed at several levels of the skeleton where the bone mineralization does not change over a follow-up of 5-6 years (Cleemann et al., 2011) . Turner syndrome patients, however, continue to have an increased fracture risk, and that may be inherent to a particular abnormality of their trabecular microarchitecture, which has recently been demonstrated with high-resolution peripheral quantitative CT scanning, despite the fact that these women are maintained on appropriate hormone replacement therapy (Cleemann et al., 2017 ).
An interesting study looked at the use of very low dose, "ultralow" estrogen therapy given to TS children between 5 and 13 years of age. This study randomized girls to either receive growth hormone or placebo injections for childhood growth promotion, and also get either very low-dose estrogen or placebo orally during that childhood age range-before puberty. The girls were subsequently induced in a standard manner around 12 years of age for further puberty induction (Ross et al., 2011) . The first outcome result showed that there was a modest growth synergistic effect with exposure of low-dose estrogen in childhood. This yielded an additional 2.1 cm, or 0.3 standard deviation improvement in adult height. For the secondary outcome of breast development onset and cadence of puberty progression, estrogen-treated patients during childhood had an earlier onset of breast development: 11.5 versus 12.5 years, followed by a median age of menarche of 15 years for both groups, that is, girls treated with low-dose estrogen in childhood and girls treated with placebo. The estrogen-treated patients had therefore a slower tempo of puberty, or took more time between entering Tanner stage II breast development and their onset of menstrual cycles. It may be that exposure to low-dose estrogen in TS childhood may be "physiological" and allow for a more appropriate cadence of progression of puberty (Quigley et al., 2014) .
| Other benefits
Effects on metabolism are usually positive. The hepatic effects on lipids do not seem to be clinically different between transdermal and oral estradiol. Liver enzyme elevations occur in TS patients, which may peak during the adolescent years (Mauras, Shulman, Hsiang, Balagopal, & Welch, 2007) . Exposure to estrogen seems to improve this, although withdrawal at a later age does not seem to alter this (Elsheikh, Hodgson, Wass, & Conway, 2001 Neurocognitive effects: Hormone replacement therapy with estrogen in TS girls seems to improve motor speed and verbal and nonverbal processing time (Ross, Roeltgen, Feuillan, Kushner, & Cutler, 1998 ). There are data that have demonstrated improvement in self-esteem and psychological well-being in adolescents and in the parent-reported problem behaviors in these girls (Ross, Roeltgen, Feuillan, Kushner, & Cutler, 2000) . Data in adults have not been so optimistic. Adult women with TS seem to have ongoing spatial and perceptual skills difficulties, difficulties with visual-motor integration, effect recognition, visual memory, attention, and executive function despite being on adequate hormone replacement therapy (Ross et al., 1996) .
| RISKS OF ESTROGEN THERAPY IN TS INDIVIDUALS
Data from a large meta-analysis of observational trials showed that the odds ratio for thromboembolic events is twice as high in women treated with oral estrogens versus transdermal estrogens compared with nonestrogen treated women, postmenopausal (Renoux, Dell'aniello, Garbe, & Suissa, 2010) . This was confirmed in a large prospective study of over a million women, showing that transdermal estrogens did not increase the relative risk for thromboembolism (Sweetland et al., 2012) . 
